查尔斯河实验室的盈利预期超出预期，但尽管利润率为负且分析师情绪复杂，其股价仍上涨。 Charles River Laboratories beat earnings estimates, but its stock rose despite a negative margin and mixed analyst sentiment.

Jporgan将查尔斯河实验室的价格目标从165美元提高到190美元,维持了“中性”评级,因为股票上涨到197.28美元,季度收入强劲,每股2.43美元,估计比预期多11美元,收入10亿美元,略高于预期,尽管年年下降0.5%。 JPMorgan raised Charles River Laboratories' price target to $190 from $165, maintaining a "neutral" rating, as the stock rose to $197.28 amid strong quarterly earnings of $2.43 per share, beating estimates by $0.11, and $1 billion in revenue, slightly above expectations despite a 0.5% year-over-year decline. 该公司的负净差为2.07%,物价与收入之比为-126.37,分析家预测该年的EPS为9.36美元。 The company posted a negative net margin of 2.07% and a price-to-earnings ratio of -126.37, with analysts forecasting $9.36 EPS for the year. 一个协商一致的“机动购买”评级和一个194.07美元的平均目标反映了不同情绪,而机构所有权仍然高达98.91%。 A consensus "Moderate Buy" rating and a $194.07 average target reflect mixed sentiment, while institutional ownership remains high at 98.91%.